For all measurements, a significant decrease (24%) of median AF-values was noted when comparing levels at baseline (n = 120, median 0.0066, IQR 0.0058–0.0080) and after FN3K (n = 120, median 0.0050, IQR 0.0046–0.0057) treatment (P < 0.0001, Figure 2b). This evidence concerns the gene FN3K and atrial fibrillation.